JP3731983B2 - Drugs for improving night noise in dementia dogs - Google Patents

Description

【００１１】
診断基準に基づき、結果を表２に示す。
【表２】

投与前のスコアは８１点、特に問題項目は鳴き声であったが、投与後鳴き声は著明な改善が見られ３日目にはかなりよくなり、２週間目には正常までに回復し、著効と判定された。
【００１２】
試験例２：犬の痴呆に対するエイコサペンタエン酸エチルエステルの治療効果試験
痴呆症状を示す１６歳のプードル犬に対し、アンプルに封入して−２０℃で保存されたエイコサペンタエン酸エチルエステルを０．５ｇ／頭／日を２３日間経口投与した。効果判定は、試験例１と同様に内野富弥らにより考案された痴呆症の診断基準（第２案）〔１００点法〕（表１）に基づいて判定した。
【００１３】
診断基準に基づき、結果を表３に示す。
【表３】

投与前のスコアは９０点、特に問題となった項目は夜中に鳴き出すことであり、その他に感情の表出、相互関係及び総合判断も最高得点であり、重度の痴呆であった。投与開始２週間後にこれらの所見は劇的に改善され、スコア合計は漸次減少し、２３日目には４６点以下に低下し、著効と判定された。
【００１４】
試験例３：犬の痴呆に対するエイコサペンタエン酸エチルエステルの治療効果試験
痴呆症状を示す１７歳のポメラニアン犬に対し、アンプルに封入して−２０℃で保存されたエイコサペンタエン酸エチルエステルを１．０ｇ／頭／日を１５日間経口投与した。効果判定は、試験例１と同様に内野富弥らにより考案された痴呆症の診断基準（第２案）〔１００点法〕（表１）に基づいて判定した。
【００１５】
診断基準に基づき、結果を表４に示す。
【表４】

投与前のスコアは８７点、特に問題となった項目は鳴き声であり、投与開始１週間後からこの症状は改善され、スコア合計は漸次減少し、２週間目には７０点まで低下し、有効と判定された。
【００１６】
試験例４：犬の痴呆に対するエイコサペンタエン酸エチルエステルの予防効果試験
痴呆予備軍と判定された１４歳の雑種犬に対し、アンプルに封入して−２０℃で保存されたエイコサペンタエン酸エチルエステルを１．０ｇ／頭／日を２３日間経口投与した。効果判定は、試験例１と同様に内野富弥らにより考案された痴呆症の診断基準（第２案）〔１００点法〕（表１）に基づいて判定した。
【００１７】
診断基準に基づき、結果を表５に示す。
【表５】

投与前のスコアは４９点、特に問題となった項目は鳴き声であり、投与後からこの症状は改善され、スコアは漸次減少、またその他の項目も改善がみられ、スコア合計は２５点まで低下し、有効と判定された。
【００１８】
【発明の効果】
本発明に従えば、ドコサヘキサエン酸および／またはエイコサペンタエン酸を痴呆症状を呈する、または高齢の伴侶動物に対し投与することにより、食欲、生活リズム、夜鳴き、旋回運動、排泄状態、感覚異常、姿勢、感情表出及び相互関係などを改善することができ、伴侶動物の脳機能改善、痴呆予防、痴呆治療に優れた効果を得ることができる。[0001]
The present invention relates to an agent for improving night noise in demented dogs containing docosahexaenoic acid and eicosapentaenoic acid as active ingredients.
[0002]
[Prior art]
Statistically, in recent years, aging of companion animals such as dogs has been confirmed, and various diseases associated with aging have become a problem for companion animals raised at home. Among them, the most problematic is the abnormal behavior of dogs. And these dogs are called dog blur because they show similar symptoms to human dementia. These dogs take a lot of time and labor to raise at home, and because they make an unusual cry, they care about their neighbors, and wandering at midnight increases the mental and physical burden of the owner due to lack of sleep. There is a phenomenon that the QOL between companion animals and their owners collapses. However, the improvement of brain function, dementia prevention and dementia treatment similar to those of humans have not been studied for dogs and cats.
[0003]
It is an object of the present invention to provide a medicine for improving the night squeezing symptoms of dogs, who are companion animals that have been left untreated or have been euthanized by the intentions of their owners when they have dementia symptoms.
[0004]
As a result of repeated studies to solve the above-mentioned problems, the present inventors have found that administration of docosahexaenoic acid and eicosapentaenoic acid to a demented symptom dog, which is a companion animal, has an excellent effect in improving night noise. The present invention has been completed.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
The docosahexaenoic acid and eicosapentaenoic acid used in the present invention may be any of free salts, salts, esters, glycerides, phospholipids, choline compounds, ascorbic acid compounds, amino acid compounds and the like.
[0006]
As for the administration route, oral administration and injection administration can be considered, but oral administration is preferred from the viewpoint of cost, convenience and safety. The dosage forms for oral administration include tablets, powders, syrups, solutions, soft capsules, ampoules and the like.
[0007]
The dose of docosahexaenoic acid and eicosapentaenoic acid varies depending on the body weight of the dog, but is 0.1 to 5.0 g / head / day, preferably 0.2 to 2.0 g / head / day. The administration period varies depending on the severity of night crying symptoms, but is generally 2 to 4 weeks.
[0008]
A companion animal refers to mammals such as dogs and cats kept close to humans.
[0009]
【Example】
EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, these are mere illustrations and these do not limit the scope of the present invention.
[0010]
Test Example 1: Therapeutic effect test of docosahexaenoic acid ethyl ester for dementia in dogs 0.5 g / head of docosahexaenoic acid ethyl ester sealed in an ampoule and stored at −20 ° C. for an 18-year-old hybrid dog showing dementia symptoms / Day was orally administered for 2 weeks. The effect was determined based on the diagnostic criteria for dementia devised by Tomoya Uchino et al. (2nd plan) [100 point method] (Table 1).
[Table 1]

[0011]
The results are shown in Table 2 based on the diagnostic criteria.
[Table 2]

The score before administration was 81 points, and the problem item was crying, but the crying after administration was markedly improved and improved considerably on the 3rd day. It was determined to be effective.
[0012]
Test Example 2: Treatment effect test of eicosapentaenoic acid ethyl ester for dementia in dogs 0.5 g of eicosapentaenoic acid ethyl ester stored in an ampoule and stored at -20 ° C for a 16 year old poodle dog showing dementia symptoms / Head / day was orally administered for 23 days. The effect was determined based on the diagnostic criteria for dementia (2nd plan) [100 point method] (Table 1) devised by Tomoya Uchino et al.
[0013]
The results are shown in Table 3 based on the diagnostic criteria.
[Table 3]

The score before administration was 90 points, and the particularly problematic item was to cry out in the night. In addition, the expression of emotions, correlation and comprehensive judgment were also the highest score, and severe dementia. Two weeks after the start of the administration, these findings were dramatically improved, and the total score gradually decreased and decreased to 46 points or less on the 23rd day.
[0014]
Test Example 3: Therapeutic effect test of eicosapentaenoic acid ethyl ester for dog dementia 1.0 g of eicosapentaenoic acid ethyl ester stored in an ampoule and stored at -20 ° C for a 17-year-old Pomeranian dog showing dementia symptoms / Head / day was orally administered for 15 days. The effect was determined based on the diagnostic criteria for dementia (2nd plan) [100 point method] (Table 1) devised by Tomoya Uchino et al.
[0015]
The results are shown in Table 4 based on the diagnostic criteria.
[Table 4]

The score before administration was 87 points, and the particularly problematic item was cry. This symptom improved from 1 week after the start of administration, the total score gradually decreased, and it decreased to 70 points at 2 weeks. It was determined.
[0016]
Test Example 4: Eicosapentaenoic acid ethyl ester prevention test for dementia in dogs Eicosapentaenoic acid ethyl ester stored in an ampoule and stored at -20 ° C for a 14-year-old hybrid dog determined to be a dementia reserve 1.0 g / head / day was orally administered for 23 days. The effect was determined based on the diagnostic criteria for dementia (2nd plan) [100 point method] (Table 1) devised by Tomoya Uchino et al.
[0017]
The results are shown in Table 5 based on the diagnostic criteria.
[Table 5]

The score before administration was 49 points, and the particularly problematic item was cry. The symptoms improved after administration, the score gradually decreased, and other items also improved, and the total score decreased to 25 points. And determined to be effective.
[0018]
【The invention's effect】
According to the present invention, by administering docosahexaenoic acid and / or eicosapentaenoic acid to a dementia symptom or an elderly companion animal, appetite, life rhythm, night cry, turning movement, excretion state, sensory abnormalities, posture, Emotional expression and correlation can be improved, and excellent effects in improving brain function, dementia prevention and dementia treatment of companion animals can be obtained.

Claims (1)

A night squeeze improving drug for demented dogs housed at home containing 0.1 to 5.0 g / head / day containing docosahexaenoic acid and eicosapentaenoic acid as active ingredients.